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The Journal of Immunology
A Small Molecule Inhibitor of ITK and RLK Impairs Th1
Differentiation and Prevents Colitis Disease Progression
Hyoung-Soo Cho,* Hyun Mu Shin,* Helena Haberstock-Debic,† Yan Xing,†
Timothy D. Owens,† Jens Oliver Funk,† Ronald J. Hill,† J. Michael Bradshaw,† and
Leslie J. Berg*
In T cells, the Tec kinases IL-2–inducible T cell kinase (ITK) and resting lymphocyte kinase (RLK) are activated by TCR
stimulation and are required for optimal downstream signaling. Studies of CD4+ T cells from Itk2/2 and Itk2/2Rlk2/2 mice have
indicated differential roles of ITK and RLK in Th1, Th2, and Th17 differentiation and cytokine production. However, these
findings are confounded by the complex T cell developmental defects in these mice. In this study, we examine the consequences of
ITK and RLK inhibition using a highly selective and potent small molecule covalent inhibitor PRN694. In vitro Th polarization
experiments indicate that PRN694 is a potent inhibitor of Th1 and Th17 differentiation and cytokine production. Using a T cell
adoptive transfer model of colitis, we find that in vivo administration of PRN694 markedly reduces disease progression, T cell
infiltration into the intestinal lamina propria, and IFN-g production by colitogenic CD4+ T cells. Consistent with these findings,
Th1 and Th17 cells differentiated in the presence of PRN694 show reduced P-selectin binding and impaired migration to CXCL11
and CCL20, respectively. Taken together, these data indicate that ITK plus RLK inhibition may have therapeutic potential in Th1-
mediated inflammatory diseases. The Journal of Immunology, 2015, 195: 4822–4831.
T
he Tec family tyrosine kinases play a key role in Ag re-
ceptor–mediated signaling pathways in lymphocytes. Among
these kinase family members, T cells express IL-2–inducible
kinase (ITK), resting lymphocyte kinase (RLK), and tyrosine kinase
expressed in hepatocellular carcinoma (1). Although each of these
kinases is expressed in mature naive T cells, ITK is the most pre-
dominant. Based on mRNA analysis, RLK is expressed at 3- to 10-
fold lower levels than ITK, and Tec is 30- to 100-fold reduced
compared with ITK (2, 3). Following TCR stimulation, ITK is acti-
vated and directly phosphorylates phospholipase C (PLC)g1. Acti-
vated PLCg1 hydrolyzes phosphatidylinositol 4,5-biphosphate to
produce inositol triphosphate and diacylglycerol, secondary mes-
sengers that lead to Ca2+ influx and MAPK and protein kinase C
activation (4). As a consequence, Itk2/2 T cells have significant
defects in T cell activation and differentiation (5–8). For RLK, some
evidence supports a role in TCR signaling, as Itk2/2Rlk2/2 double-
deficient T cells are more impaired than those lacking only ITK (5,
9). Nonetheless, based on present data, the precise functions of RLK
and tyrosine kinase expressed in hepatocellular carcinoma in T cell
activation are unclear.
To elucidate the role of Tec kinases in TCR signaling, several
studies have addressed the impact of a deficiency in ITK, or ITK
plus RLK, in CD4+ Th cell differentiation and function. Initial
studies showed that Itk2/2 mice exhibited impaired Th2 differ-
entiation and Th2-biased responses to parasitic infection, with
little effect on protective Th1 responses to intracellular protozoans
(2, 10). These data were further supported by controlled in vitro
studies that demonstrated that naive Itk2/2 CD4+ T cells were
defective in Th2 but not Th1 differentiation, in part due to the fact
that differentiated Th2 cells fail to express any RLK protein, as do
Th1 cells (2). Additionally, ITK and RLK functions in Th cells are
at least partially redundant, as RLK overexpression in Itk2/2 mice
was able to restore Th2 responses in animal models of allergic
asthma and schistosome egg–induced lung granuloma formation
(11). Nonetheless, it has been difficult to distinguish which phe-
notypes observed in these mice are due to the functions of ITK
and/or RLK in mature naive CD4+ T cells, and which are the
consequence of altered T cell development generating an abnor-
mal cytokine environment in the Itk2/2 or Itk2/2Rlk2/2 mice.
More recently, studies by Schwartzberg and colleagues (12, 13)
have indicated an additional role for ITK in Th17 differentiation.
Specifically, Itk2/2 T cells showed reduced IL-17A production
and increased Foxp3 expression following in vitro polarization.
Additionally, Itk2/2 T cells provided enhanced regulatory T cell
(Treg)–mediated protection in an adoptive transfer model of colitis
owing to their increased potential to upregulate Foxp3 (13), al-
though another study found that Itk2/2 Tregs were unable to
protect against T cell–mediated colitis (14). Despite some dis-
parities between studies, in general, these findings have provided
impetus for the development of small-molecule ITK kinase in-
hibitors, with the intent of using them as treatments for atopic
diseases, as well as for their potential as an immunosuppressant to
block graft rejection or autoimmunity.
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The complex phenotype of Itk2/2 mice, including defects in
T cell development, activation, differentiation, and effector func-
tion, has made it difficult to precisely assess the function of ITK in
each lineage of T cells and at different stages of an immune re-
sponse. It has also been challenging to distinguish functions of
ITK in T cell activation and differentiation from effects due to
altered T cell development in Itk2/2 mice. A more direct strategy
to address ITK and/or RLK function in T cells is to use a selective
small-molecule inhibitor of these Tec kinases. PRN694 is a small
molecule that forms an irreversible covalent bond with C442 in
ITK or C350 in RLK, and it has recently been shown to selectively
inhibit ITK and RLK in T cells (15). To date, the inhibitory effects
of PRN694 on CD4+ Th cell differentiation and effector function
have not been tested.
In this study, we examined the effects of PRN694 on CD4+
T cell differentiation and function in vitro and in vivo. Surpris-
ingly, we found that PRN694 showed potent inhibitory effects on
Th1 differentiation and IFN-g production as well as on Th17
differentiation and IL-17A production, with decreased potency
on Th2 differentiation. To test the relevance of this inhibitory
activity in vivo, we used the T cell adoptive transfer model of
colitis, an inflammatory condition mediated by IFN-g–producing
Th1 cells (16, 17). Consistent with our in vitro data, PRN694
administration ameliorated colitis disease progression and
markedly inhibited colonic inflammation. Taken together, these
data indicate that simultaneous inhibition of ITK and RLK by a
small-molecule inhibitor may be an effective treatment for Th1-
biased inflammatory diseases.
Materials and Methods
Mice
C57BL/6 wild-type (WT), C57BL/6 Rag22/2, C57BL/6 OT-II Rag12/2
TCR transgenic (Tg), and B10.A 5C.C7 Rag22/2 TCR Tg mice were
purchased from Taconic Biosciences and housed in specific pathogen-free
conditions at the University of Massachusetts Medical School in accor-
dance with Institutional Animal Care and Use Committee guidelines. CD-1
mice were purchased from Charles River Laboratories; all housing and
procedures with these mice were in accordance with the guidelines ap-
proved by Principia Biopharma’s Institutional Animal Care and Use
Committee.
Th cell polarization and CFSE dilution assay
Naive CD4+ T cells (3.0 3 105) from B10.A 5C.C7 Rag22/2 TCR Tg or
C57BL/6 OT-II Rag12/2 TCR Tg mice were isolated using CD4 (L3T4)
microbeads (Miltenyi Biotec). Isolated cells were plated in 12- or 24-well
plates and activated by plate-bound anti-CD3 (1.0 mg/ml) and anti-CD28
(4.0 mg/ml) (BD Biosciences) for 72 h in the presence of the following
conditions: Th0 (anti-CD3/CD28 with no cytokines), Th1 (IL-12, 10 ng/ml
plus anti–IL-4, 10 mg/ml), Th2 (IL-4, 10 ng/ml plus anti–IFN-g, 10 mg/ml),
Th17 (IL-6, 20 ng/ml, TGF-b, 5.0 ng/ml, IL-1b, 20 ng/ml plus anti–IFN-g,
anti–IL-4, and anti–IL-2, each at 10 mg/ml) (all anti-cytokine Abs were
purchased from R&D Systems and BD Biosciences). For CFSE dilution
assay, CD4+ T cells isolated by magnetic separation were resuspended in 1.0
ml 13 PBS with 0.1% BSA at 5.0 3 106 cells/ml. Then, cells were stained
with CFSE at a final concentration of 2.0 mM at 37˚C for 10 min. After
incubation, stained cells were quenched by adding 5 vol ice-cold RPMI
1640 complete medium (10% FBS) for 5 min on ice. Cells were washed
three times with complete medium and then plated for Th polarization for
72 h.
Cytokine and transcription factor analysis
T cells were stimulated with PMA (50 ng/ml) and ionomycin (1.0 mg/ml)
for 5 h with protein transport inhibitors, GolgiStop and GolgiPlug (BD
Biosciences), each at 1.0 mg/ml. All cells were first stained with Abs to
CD4 and CD44 (BD Biosciences) and a Live/Dead fixable aqua dead cell
stain kit (Life Technologies). Stained cells were then fixed and per-
meabilized by using a BD Cytofix/Cytoperm kit (BD Biosciences). For
cytokine staining, cells were stained with Abs to IFN-g, IL-4, IL-17A, or
IL-2 (BD Biosciences). For transcription factor staining, cells were fixed
and permeabilized using a Foxp3/transcription factor staining buffer set
(eBioscience) and stained with Abs to T-bet, GATA-3, retinoic acid–related
orphan receptor gt, or Foxp3 (BD Biosciences). Cells were analyzed on an
LSR II flow cytometer (BD Biosciences), and data were analyzed with
FlowJo (Tree Star).
Measurements of cytokine production by human PBMCs and
in-mouse plasma
Human PBMCs isolated from whole blood were incubated for 1 h with and
without PRN694 and stimulated with plate-bound anti-CD3 (2.5 mg/ml)
and soluble anti-CD28 (1.0 mg/ml) (BD Biosciences) for 18 h. Super-
natants were collected, frozen, and analyzed using the human Inflam-
mationMAP v.1.0 biomarker panel (Myriad RBM). For the IL-2
inhibition dose response, PBMCs were incubated for 1 h with a con-
centration range of PRN694 and stimulated either with anti-CD3/CD28
or 10 mM thapsigargin (Sigma-Aldrich) for 18 h. Supernatants were
analyzed for IL-2 using the AlphaLISA IL-2 kit (PerkinElmer). For
cytokine inhibition in vivo, triplicate CD-1 mice were administered a 20
mg/kg i.p. dose of PRN694 followed either 1 or 6 h later by adminis-
tration of 10 mg/mouse anti-CD3 (R&D Systems). Plasma was collected
2 h after anti-CD3 injection and analyzed for cytokines using the
RodentMAP v.3.0 biomarker panel (Myriad RBM).
Mouse adoptive transfer colitis model and PRN694
administration
CD4+CD45RBhi T cells were sorted from spleens of C57BL/6 WT mice,
and 4.0 3 105 cells were injected i.p. into Rag22/2 hosts. Recipient mice
were weighed daily and sacrificed 7 wk posttransfer, at which time
colons were removed for length measurement, histologic analysis,
and lymphocyte isolation, and lymphoid organs were harvested for
flow cytometry analysis. Vehicle (5% ethanol/95% Captex 355 EP/
NF, ABITEC) or PRN694 was orally administered according to the
following regimen: once a day (40 mg/kg) for weeks 0–2 and 4–7, and
twice a day (20 mg/kg) for weeks 2–4.
Histologic examination of colon
Colon specimens obtained from vehicle-treated or PRN694-treated hosts
were fixed in 10% buffered formalin and stained with H&E. To assess the
severity of colitis, histologic scores of the proximal, middle, and distal
colon were examined.
In vivo PRN694 target engagement assay and assessments of
toxicity
Naive C57BL/6 mice were dosed with vehicle or PRN694 (40 mg/kg). After
2 or 6 h of oral administration, the dosed mice were sacrificed and CD4+
T cells were isolated from the spleen by using an EasySep mouse CD4+
T cell isolation kit (StemCell Technologies). Then, isolated CD4+ T cells
were stimulated with anti-CD3 (10 mg/ml) and anti-CD28 (5.0 mg/ml) for
5 min at 37˚C. After stimulation, CD4+ T cells (4.0 3 106) were lysed by
CelLytic M buffer (Sigma-Aldrich) containing proteinase and phosphatase
inhibitor. The expression of phosphorylated PLCg1 and total PLCg1 was
examined by Western blot using anti–p-PLCg1 (Tyr783) mAb and anti–
PLCg-1 mAb (D9H10) (Cell Signaling Technology) at 1:1000 dilution.
The secondary Ab was Alexa Fluor 647–conjugated anti-rabbit IgG (H+L)
(Invitrogen) at 1:1000 dilution, and the signal was evaluated using a Ty-
phoon biomolecular imager (GE Healthcare Life Sciences) with signal
quantification using ImageQuant TL 7.0 software (GE Healthcare Life
Sciences). Following long-term in vivo administration, we noted that the
mice treated with PRN694 gained weight comparable to control untreated
Rag22/2 controls and showed no behavioral indications of drug-mediated
toxicity. Furthermore, to address whether PRN694 might be generally
cytotoxic, we examined the inhibition of proliferation of the HCT116
colorectal carcinoma cell line in the presence or absence of PRN694 and
found an IC50 of 10 mM in this assay. Because this is a concentration
higher than the maximum concentration of PRN694 in plasma following a
40 mg/kg oral dose, we concluded that PRN694 had no apparent toxicity
during the 7-wk dosing time frame.
Isolation of intraepithelial lymphocytes and lamina
propria lymphocytes from the colon
Colons were opened longitudinally and then cut into 1- to 2-cm pieces.
After incubation with EDTA and DTT in HBSS at 37˚C for 20 min with
vigorous vortexing, the cell suspension was passed through a 70-mm
strainer, and the flow-through containing intraepithelial lymphocytes
(IELs) was collected by centrifugation. For lamina propria (LP) lympho-
cytes, the remaining tissues were digested with collagenase D (Roche), Dispase
The Journal of Immunology 4823
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II (Roche), and DNase I (Roche) at 37˚C for 20 min and then vortexed vig-
orously. Final cell suspensions were isolated using 40/80% Percoll (GE
Healthcare Life Sciences) density gradients, and the viability of extracted cells
was tested using trypan blue.
P-selectin glycoprotein ligand-1 binding and cell migration
assays
Naive CD4+ T cells were isolated with CD4 (L3T4) microbeads (Miltenyi
Biotec) and then cultured in the presence or absence of PRN694 (25 or 50
nM) for 72 h in each Th polarization condition as described above. For
P-selectin glycoprotein ligand 1 binding assay, cultured and polarized
CD4+ T cells were first treated with 2.4G2 Fc Block (anti-CD16/CD32)
for 10 min at 4˚C and then washed with FACS buffer (13 PBS con-
taining 5.0% FBS). Recombinant P-selectin–human IgG fusion protein
(BD Biosciences) was added to the cells (1:200 dilution) at 4˚C for 30
min. Cells were washed and then stained with allophycocyanin-conjugated
anti-human IgG (Jackson ImmunoResearch Laboratories) and surface marker
Abs. The cell migration assay was performed by using HTS Transwell-96
well permeable supports with 3.0-mm pores (Corning). Cultured CD4+ T cells
were washed twice and resuspended at 2.5 3 106 cells/ml with serum-free
RPMI 1640 containing 0.1% BSA. Lower chambers were loaded with 200 ml
diluted chemokines (CXCL11, 100 ng/ml; CCL20, 100 ng/ml; CCL25, 300
ng/ml) (PeproTech and R&D Systems). Twenty-five microliters cell suspen-
sion (5.0 3 105 cells) was loaded in the upper chamber of a polycarbonate
filter. Cell migration was performed at 37˚C, 5% CO2 for 3 h, and non-
migrated cells on the upper chamber were rinsed off with 13 PBS containing
0.1% BSA. After centrifugation (1500 rpm for 10 min), the upper chamber
was removed and the migrated cells were resuspended in 13 PBS with 0.1%
BSA. The numbers of migrated cells were counted by the flow cytometer. To
calculate the chemotaxis index, the numbers of cells migrated in response to
each chemokine were divided by the numbers of spontaneously migrated
cells.
Statistical analysis
Data are represented as mean 6 SEM. Statistically significant differences
were determined by a Student t test.
Results
Inhibition of ITK and RLK kinases potently inhibits CD4+ Th
cell differentiation
To determine the consequences of Tec kinase inhibition on Th
differentiation, we used a recently reported small-molecule cova-
lent inhibitor of ITK and RLK, PRN694 (Fig. 1A) (15). Based on
in vitro kinase assays, PRN694 is a potent inhibitor of all three Tec
kinases expressed in T cells, demonstrates less potency toward the
other Tec kinases BTK and BMX (Fig. 1B), and shows excellent
kinome-wide selectivity (15). As reported, PRN694 binds covalently
to a conserved cysteine residue in the ATP binding sites of ITK and
RLK (ITK C442, RLK C350) and is highly selective for these two
kinases in T cells (15). Unlike its binding to ITK and RLK, PRN694
does not appear to bind covalently to BTK and hence displays a
limited duration of BTK inhibition biochemically and in cells (15).
Furthermore, PRN694 is 63- to 320-fold more potent in inhibiting
ITK than previously described ITK inhibitors, for example, BMS-
509744 and BMS-488516 (Fig. 1B) (18–22).
To assess the potential effect of PRN694 on CD4+ Th cell
differentiation, we used naive CD4+ T cells from B10.A 5C.C7
Rag22/2 TCR Tg mice and stimulated these cells under Th1-,
Th2-, or Th17-polarizing conditions. Cells were cultured for 3 d in
the presence of increasing doses of PRN694 and then analyzed for
cytokine production after restimulation with PMA and ionomycin
for 5 h. Among these conditions, PRN694 inhibited Th1 differ-
entiation more potently than was observed for Th2 and Th17
differentiation. Whereas a low concentration of PRN694 (25 nM)
inhibited IFN-g production by Th1 cells by .50%, 50–100 nM
PRN694 was required to achieve a similar level of inhibition of
IL-17A production by Th17 cells (Fig. 1C, 1D). Furthermore,
none of the doses tested achieved 50% inhibition of IL-4 pro-
duction by Th2 cells. The effects of PRN694 on cytokine pro-
duction did not correlate with effects on cell proliferation
(Supplemental Fig. 1A, 1B), indicating that the inhibition of IFN-g
production by Th1 cells was not due to reduced proliferation of
these cells in the presence of PRN694.
We also examined the expression of Th cell lineage-determining
transcription factors. Overall, the expression levels of all tran-
scription factors tested (T-bet, GATA-3, and retinoic acid–related
orphan receptor gt) were decreased upon the inhibitor treatment;
however, the modest differences observed between the three
Th cell lineages did not correlate precisely with diminished cyto-
kine production (Fig. 1E). Collectively, these data indicate that
PRN694 specifically targets ITK and RLK kinase activity and also
impairs CD4+ Th cell differentiation and cytokine production, with
a range of potency as follows: Th1 . Th17 . Th2.
PRN694 inhibits TCR-induced cytokine production from
human PBMCs and in mouse plasma
To further study the effect of dual ITK/RLK inhibition on T cell
function, human PBMCs were stimulated with anti-CD3/CD28
in both the absence and presence of PRN694, and the cytokines
produced after 18 h were measured using a biomarker panel. We
used both a moderate (20 nM) and high (5.0 mM) concentration of
PRN694 and focused on cytokines that were robustly induced in
this short-term assay, including IFN-g, IL-6, and IL-2. The in-
crease in each of these cytokines induced by anti-CD3/CD28
stimulation was completely blocked by 5.0 mM PRN694 and
was strongly inhibited by 20 nM PRN694 (Fig. 2A, Supplemental
Table I). To quantify the potency of inhibition of IL-2 production,
a 12-concentration dose range of PRN694 was tested. These data
indicated an IC50 value of 8.76 2.1 nM (Fig. 2B). To confirm that
the inhibition of IL-2 production was due to selective ITK and
RLK inhibition, we bypassed the requirement for these kinases by
stimulating PBMCs with the calcium pump inhibitor thapsigargin,
and we observed that the ability of PRN694 to inhibit IL-2 pro-
duction was strongly impaired (Fig. 2B). To determine whether
PRN694 inhibited these cytokine responses in vivo, mice were
injected with a 20 mg/kg i.p. dose of PRN694, followed by in-
jection of anti-CD3 either 1 or 6 h later to stimulate cytokine
production. Plasma was collected 2 h after anti-CD3 injection, and
cytokines were analyzed using a cytokine biomarker panel (Fig.
2C). The robust increase in IFN-g, IL-6, and IL-2 induced by anti-
CD3 stimulation was inhibited by PRN694 at both time points
(Fig. 2C, Supplemental Table II).
PRN694 treatment in vivo ameliorates symptoms in the CD4+
CD45RBhi T cell transfer model of colitis
Owing to the potent inhibitory effect of PRN694 on IFN-g produc-
tion by Th1 cells in in vitro culture experiments, we considered
whether PRN694 might function in vivo to suppress a Th1/IFN-g–
mediated disease. To test this hypothesis, we adoptively transferred WT
colitogenic CD4+CD45RBhi T cells from C57BL/6 mice into RAG2-
deficient hosts and monitored the mice for weight loss as a surrogate
for disease progression. Previous studies have demonstrated that the
colitis induced in this model is due to Th1-mediated inflammation,
with little involvement of Th2 or Th17 effector responses (16, 23,
24). In addition to the transferred cells, mice received vehicle alone
or PRN694 by oral gavage. Based on studies of ITK target occu-
pancy in thymocytes following in vivo administration of PRN694 in
mice (15), we dosed mice daily and, for a 2-wk period (weeks 2–4),
twice daily (Fig. 3A). As expected, recipient mice receiving vehicle
alone failed to gain weight and progressively lost weight, beginning
4 wk after T cell transfer. In contrast, PRN694-treated mice exhibited
no weight loss and remained similar to control RAG2-deficient mice
that did not receive a colitogenic T cell transfer (Fig. 3B). Consistent
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with these data, analysis of colon length at 7 wk posttransfer indi-
cated that the reduced colon length seen in the vehicle-treated mice
was prevented in the PRN694-treated mice (Fig. 3C). Additionally,
histological analysis of the colonic epithelium revealed lymphocytic
infiltration in the colon of the vehicle-treated mice (Fig. 3D), in
contrast to the reduced inflammation seen in the colon of PRN694-
treated mice. To further confirm target engagement of PRN694 with
ITK in vivo, splenic CD4+ T cells were isolated from vehicle-dosed
or PRN694-dosed mice (2 or 6 h posttreatment) and then stimulated
with anti-CD3/CD28 mAb to examine PLCg1 phosphorylation. As
shown, the phosphorylation of PLCg1 was completely blocked at
both time points following PRN694 administration (Supplemental
Fig. 1C). Taken together, these data demonstrate that PRN694 re-
duces T cell–mediated colonic inflammation by inhibiting ITK/RLK.
PRN694 impairs IFN-g–mediated Th1 responses and prevents
T cell migration to the inflamed colon
To determine the basis of PRN694-mediated inhibition of colitis,
we analyzed the T cell populations in the spleen, mesenteric lymph
node (mLN), intestinal epithelium (intraepithelial lymphocytes [IELs]),
and LP of recipient Rag22/2mice at 7 wk posttransfer. Assessment of
CD4+ T cell proportions did not reveal any significant differences in
the spleens or mLNs between the vehicle- or PRN694-treated mice,
although a modest but significant difference in absolute numbers of
CD4+ T cells was observed in mLNs (Fig. 4A, 4B). However, CD4+
T cell proportions in intestinal epithelium and LP of PRN694-treated
mice were significantly less than those seen in the vehicle-treated
mice, along with a statistically significant difference in absolute
numbers in the LP (Fig. 4A, 4B). To test whether PRN694 exerted any
inhibitory effect on T cell function, we examined cytokine production
from transferred colitogenic T cells in several different organs after a
brief in vitro stimulation. As expected, CD4+ T cells showed robust
IFN-g production in all analyzed sites of vehicle-treated mice,
whereas no IL-17A production was observed (Fig. 4C). Interestingly,
PRN694 administration markedly reduced the proportions of CD4+
T cells producing IFN-g in mLNs, IELs, and LP, although this effect
was less prominent in the spleen (Fig. 4C, 4D). There was also a large
decrease in the numbers of IFN-g–producing CD4+ T cells in all
FIGURE 1. PRN694 inhibits CD4+ Th cell dif-
ferentiation. (A) Chemical structure of PRN694. (B)
The selectivity and potency of PRN694 were ex-
amined by in vitro kinase assay. The table shows the
IC50 values for the kinases indicated; for the com-
plete dataset, see Zhong et al. (15). (C and D) Pu-
rified naive mouse splenic CD4+ T cells were
stimulated in Th-polarizing conditions in the pres-
ence of PRN694 at the indicated concentrations for
72 h. CD4+ T cells were then restimulated with
PMA and ionomycin for 5 h and analyzed by in-
tracellular cytokine staining. The untreated controls
were cultured in the presence of DMSO. The per-
centages of cytokine-producing CD4+ T cells (gated
on CD4+CD44hi cells) are shown (C). Compilation
of data from three independent experiments indi-
cating the inhibitory effect of PRN694 on the cy-
tokine production are shown. For each cytokine, the
data were normalized to the percentage of cytokine-
producing cells in the absence of inhibitor (D). (E)
Data from three experiments were compiled, and
for each Th transcription factor, the data were nor-
malized to the percentage of positive cells in the
absence of inhibitor. *p , 0.05, **p , 0.01, ***p ,
0.001.
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organs following PRN694 treatment, although the suppression did not
reach significance in the LP (Fig. 4E). Consistent with our in vitro
studies, the reduced production of IFN-g by T cells in the PRN694-
treated mice could not be accounted for simply by defects in ex-
pression of the Th1 transcription factor, T-bet (Supplemental Fig. 2A,
2B).
Owing to the reduced proportion of CD4+ T cells in the inflamed
intestines of PRN694-treated mice, we also investigated expres-
sion of gut-homing receptors, integrin a4b7 (LPAM-1) and CCR6,
on colitogenic T cells (25–27). Consistent with the proportions of
gut-infiltrating CD4+ T cells, expression of both integrin a4b7
and CCR6 were reduced on intestinal epithelial CD4+ T cells
when PRN694 was administered (Fig. 4F). In contrast, we did
not detect any significant level of expression of these receptors on
LP-isolated CD4+ T cells from either group of mice (Fig. 4F).
Taken together, these data strongly suggest that PRN694 attenu-
ates in vivo Th1-biased intestinal inflammation through the inhi-
bition of IFN-g production and the expression of intestine-homing
surface receptors.
PRN694 impairs induced Treg differentiation and IL-2
production by transferred colitigenic CD4+ T cells
A recent study has shown that Itk2/2 CD4+ T cells have an in-
creased propensity to upregulate Foxp3 and differentiate into in-
duced Tregs (iTregs) when stimulated under Th17-polarizing
conditions (13). We therefore considered whether the inhibitory
effect of PRN694 on colitis might be due to enhanced differen-
tiation of Foxp3+ iTregs in the inhibitor-treated mice. Instead,
analysis of T cells at 7 wk posttransfer indicated that PRN694
significantly reduced the proportions of CD4+ T cells expressing
Foxp3 compared with controls, a result consistent with the find-
ings of Huang et al. (14). This was evident in all organs examined
(Fig. 5A, 5B). Examination of surface markers commonly found
on most Tregs, including CTLA-4, PD-1, and GITR, also showed
reduced expression on Foxp3+CD4+ T cells in PRN694-treated
mice (Supplemental Fig. 2C–E).
Because upregulation of Foxp3 and iTreg differentiation are
dependent on IL-2 (28–31), we examined the effects of PRN694
on IL-2 production by in vitro polarized CD4+ T cells. As shown,
PRN694 inhibited IL-2 production by all three lineages of Th cells
(Fig. 5C, 5D). Consistent with these data, T cells from the
adoptive transfer colitis studies also showed reduced proportions
of cells capable of producing IL-2 following treatment with
PRN694 (Fig. 5E, 5F). These data indicate that reduced disease
progression in mice treated with PRN694 is not a consequence of
enhanced differentiation of Foxp3+ iTreg cells, but rather a result
of inhibition of differentiation and activation of the IFN-g–pro-
ducing Th1 effector cell population.
PRN694 inhibits P-selectin binding activity and chemokine-
induced migration of polarized Th1 and Th17 cells
Our results in the adoptive transfer colitis studies showed reduced
numbers of CD4+ T cells present in the colonic epithelium of
PRN694-treated mice compared with controls. As previous studies
FIGURE 2. PRN694 inhibits TCR-induced cy-
tokine production from human PBMCs and in
mouse plasma. (A) Human PBMCs were stimu-
lated in vitro with anti-CD3/CD28 for 18 h in the
absence or presence of PRN694 at 20 nM or 5.0
mM, and levels of IFN-g, IL-6, and IL-2 in the
supernatants were measured as part of the human
InflammationMAP v.1.0 biomarker panel. A com-
plete list of all biomarkers of the panel is found in
Supplemental Table I. Data are shown as means 6
SEM (n = 3/group). (B) A dose response of
PRN694 was used to assess the potency of inhi-
bition of IL-2 production by PBMCs. Cells were
stimulated with anti-CD3/CD28 (n) or thapsigargin
(▴). IL-2 was quantified using an AlphaLISA IL-2
immunoassay. (C) Mice were injected i.p. with
PRN694 (20 mg/kg) followed by anti-CD3 (10 mg/
mouse) 1 or 6 h later. Two hours after anti-CD3
injection, plasma was collected and cytokines were
measured as part of the RodentMAP v.3.0 bio-
marker panel. A complete list of all biomarkers of
the panel is found in Supplemental Table II. Dotted
lines indicate the detection limit for each cytokine
in the assay. Data are shown as means 6 SEM (n =
3/group). *p , 0.05, **p , 0.01.
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using naive T cells from Itk2/2 and Itk2/2Rlk2/2 mice had shown
a role for these kinases in CCL19- and CXCL12-induced migra-
tion (7, 32), we considered whether CD4+ effector T cells might
also require ITK and RLK for efficient migration into tissues.
Using CD4+ T cells polarized in vitro to Th1, Th2, or Th17
lineages in the presence or absence of PRN694, we first examined
binding to P-selectin, a ligand expressed on activated endothelium
(33). Both Th1 and Th17 cells showed reduced P-selectin binding
following differentiation in the presence of both doses of PRN694
tested; in contrast, Th2 cells showed only a modest reduction, and
this reduction was only visible in the higher dose of inhibitor
(Fig. 6A, 6B).
As a second approach, we tested migration of CD4+ effector
T cells to chemokines implicated in trafficking to the gastroin-
testinal epithelium. We focused on responses to CXCL11, a ligand
for CXCR3 commonly found on effector Th1 cells (34), CCL20, a
FIGURE 3. PRN694 administration amelio-
rates colitis disease progression. (A–D) Colito-
genic CD4+CD45RBhi splenic T cells (4.0 3
105 cells/mouse) from C57BL/6 WT mice were
injected i.p. into C57BL/6 Rag22/2 hosts. Re-
cipients were treated with vehicle (red, n = 5) or
PRN694 (blue, n = 5) with the indicated regi-
men (A), and disease progression of dosed re-
cipients and untreated (no CD4+CD45RBhi T
cell transfer) Rag22/2 controls (black, n = 4)
was monitored by weight change (B). Data are
shown as means 6 SEM. At 7 wk posttransfer,
untreated Rag22/2 control, vehicle-dosed, and
PRN694-dosed mice were sacrificed for the
measurement of colon length (C) and histologic
analysis using H&E staining (D). Data were
compiled from two independent experiments.
*p , 0.05, **p , 0.01, ***p , 0.001.
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ligand for CCR6 found on Th17 cells (35, 36), and CCL25, a li-
gand for CCR9 (37, 38), which is expressed on gut-resident T cells.
Using a Transwell migration assay, we found that PRN694 inhibited
Th1 migration to CXCL11, with little migration observed by other
subsets to this chemokine. CCL20 induced a modest degree of
migration of Th17 cells, and this migration was reduced ∼2-fold by
PRN694. Th0 and Th1 cells showed fewer cells migrating in re-
sponse to CCL20, and these responses were further reduced by
PRN694. Overall, few cells of any lineage migrated in response to
CCL25, with significant inhibition seen only in Th1 and Th0 cells.
Polarized Th2 cells showed no migration to any of the chemokines
tested (not shown). Overall, these data confirm that PRN694 im-
pacts differentiating Th1 and Th17 cells to reduce their ability to
bind to activated endothelium and to migrate to inflammatory
chemokines.
Discussion
In this study, we show that inhibition of ITK and RLK by PRN694
leads to a significant impairment in CD4+ Th cell differentiation
and to protection from Th1-mediated colitis. Although PRN694
treatment inhibited the differentiation of all CD4+ Th subsets
in vitro, the most potent inhibitory effect we observed was on Th1
differentiation. These findings are consistent with a recent study
using an allele-sensitive mutant of ITK coupled with a selective
FIGURE 4. PRN694 treatment reduces colitogenic T cell proportions and IFN-g production in the intestinal epithelium. (A and B) The proportions and
absolute numbers of CD4+ T cells in spleen, mLNs, intestinal epithelium, and colon LP are shown. (C–E) Isolated lymphocytes from various sites were
stimulated with PMA and ionomycin and analyzed for IL-17A and IFN-g production. Dot plots show gated CD4+CD44hi T cells (C). The proportions (D)
and numbers (E) of IFN-g–producing CD4+ T cells are shown. Data are compiled from two independent experiments. (F) Histograms show the expression
of gut-homing receptors, integrin a4b7 (LPAM-1) and CCR6, on colonic IELs and LP CD4
+CD44hi T cells. Numbers indicate the percentages of cells in
each region. Graph shows a compilation of data from three to five mice in each group. *p , 0.05, **p , 0.01, ***p , 0.001.
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inhibitor, which also revealed an important role for ITK kinase
activity in Th1 differentiation and cytokine production (39). Our
data with PRN694 are also consistent with previous studies
showing that Itk2/2Rlk2/2 mice mounted a normal protective type
II cytokine response against Schistosoma mansoni, but were highly
susceptible to the intracellular protozoan Toxoplasma gondii (5, 6).
Furthermore, these results strongly suggest that a dual inhibitor of
ITK and RLK would likely have a different effect on Th2-skewed
inflammation such as asthma or atopic diseases compared with an
inhibitor that was selective for ITK alone.
Also consistent with previous studies using Itk2/2 T cells
(12), we observed that PRN694 was a potent inhibitor of
Th17 differentiation and IL-17A production in vitro. None-
theless, it is unlikely that inhibition of Th17 responses can
account for the effects of PRN694 in ameliorating disease in
our colitis experiments. Although some studies have shown a
role for Th17 cells in colitis (40–42), these effects were seen
either when colitogenic BALB/c T cells were transferred to
syngeneic hosts (41) or when the cecal bacterial Ag-specific
C3H/HeJBir CD4+ T cell lines were transferred to C3H.SCID
hosts and then restimulated for 10 d in the presence of bacterial
Ag-pulsed dendritic cells and with or without IL-23 prior to
analysis (42). In contrast, a study using a protocol most similar
to our own found that colitis was actually enhanced when Th17
responses were eliminated (40), and the transfer of naive CD4+
T cells from Il17a2/2 mice still induced a severe colitis (41).
Furthermore, several other reports suggest that Th17 responses
arise early on during colitis disease progression and that
in vitro polarized Th17 cells are eventually converted into Th1
cells after adoptive transfer to lymphopenic hosts (43, 44).
Using this CD4+CD45RBhi adoptive transfer model of T cell–
mediated colitis, we were unable to detect IL-17A production
from colitogenic T cells in mice that were treated with vehicle
alone, suggesting that Th17 responses were not contributing to
disease progression in our studies. Thus, we were unable to
assess the efficacy of PRN694 to inhibit IL-17A production
in vivo in this disease model.
In the present study, we cannot rule out an effect of PRN694
on the Tec kinase family member Tec. Previous studies have
indicated that Tec mRNA expression is negligible in primary T
cells examined ex vivo, including memory phenotype cells (45)
(http://www.immgen.org), and that only modest increases in
Tec protein expression (,2-fold) are observed even after Th1
polarization in vitro (46). Furthermore, studies of T cell re-
sponses in Tec2/2 mice have failed to reveal any significant
defects due to the absence of Tec. Therefore, it seems unlikely
that the inhibitory effects of PRN694 observed in our studies
are due to its effect on Tec activity in T cells.
Interestingly, we observed reduced differentiation of Foxp3+
iTreg cells in PRN694-treated mice compared with controls. In
FIGURE 5. PRN694 treatment de-
creases Treg frequencies and IL-2
production from CD4+ T cells in vitro
and in vivo. (A and B) CD4+ T cells
from spleen, mLNs, IELs, and LP
from vehicle-treated or PRN694-treat-
ed mice at 7 wk posttransfer were ex-
amined for Foxp3 expression. (A) Dot
plots show CD4 versus Foxp3 staining,
with numbers indicating the percent-
ages of CD4+Foxp3+ Tregs, and (B)
the graph shows a compilation of data
from three to five mice in each group.
(C and D) Naive CD4+ T cells were
stimulated in Th-polarizing conditions
with PRN694 at the indicated con-
centrations for 72 h. Cells were then
restimulated with PMA and ionomycin
for 5 h and then analyzed for IL-2
production. (C) The percentages of IL-
2–producing CD4+ T cells (gated on
CD4+CD44hi) are shown. (D) Compi-
lation of data from three independent
experiments is shown, with the data for
each Th subset normalized to the per-
centage of positive cells in the absence
of inhibitor. (E and F) Isolated lympho-
cytes from vehicle-treated or PRN694-
treated mice at 7 wk posttransfer were
stimulated with PMA and ionomycin
and analyzed for IL-2 production. Plots
show gated CD4+CD44hi T cells, and
the graph shows a compilation of data
from three to five mice in each group.
*p , 0.05, **p , 0.01.
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contrast, a previous study showed increased differentiation of
Itk2/2 naive CD4+ cells into Foxp3+ iTreg cells in a similar
adoptive transfer model of colitis (13). The difference in these
two sets of findings could be due to a number of factors. First, the
numbers of cells transferred and the time points analyzed were
each different in the two studies. More importantly, there may be
an unappreciated difference in the starting populations of CD4+
CD45RBhiCD252 T cells isolated from WT mice, as in our
studies, compared with those isolated from Itk2/2 mice. Addi-
tionally, PRN694 is a potent inhibitor of both ITK and RLK, and
this dual inhibition may lead to a different outcome than the
single genetic deficiency in Itk. It is also important to consider
that a small-molecule kinase inhibitor might have a different
effect than a genetic deficiency that causes a complete absence of
ITK protein, as the former situation would not abolish any
kinase-independent functions of ITK. Finally, it is important to
consider the possibility that mice housed in two different envi-
ronments have significant differences in their microbiota, and
that these differences may impact iTreg differentiation in vivo.
Our studies indicate that PRN694 treatment reduces the numbers
of colitogenic CD4+ T cells in the intestinal epithelium at 7 wk
posttransfer. It is possible that one component of this decrease is
reduced proliferation of the T cells in the presence of PRN694,
although our in vitro studies examining proliferation suggest that
this explanation is unlikely. Instead, we propose that impaired
T cell migration to the gastrointestinal tract is contributing to this
deficit. We find that PRN694 treatment during Th cell polarization
leads to reduced P-selectin binding on Th1 and Th17 cells, an
alteration that could impact T cell rolling on the activated endo-
thelium prior to extravasation into the gastrointestinal tract. This
possibility is consistent with our previous studies showing impaired
tissue homing and transendothelial migration of Itk2/2 T cells in an
autoimmune disease model (47). Furthermore, we observed reduced
expression of integrin a4b7 and CCR6, as well as reduced in vitro
chemotaxis to inflammatory chemokines, by PRN694-treated CD4+
T cells. Taken together, these data provide strong support for the
conclusion that ITK/RLK inhibition leads to impaired T cell mi-
gration into the gastrointestinal tissue.
Overall, we show that PRN694 inhibits CD4+ effector T cell
differentiation and cytokine production, particularly for Th1 and
Th17 lineage cells. Together with the inhibitory effect of PRN694
on T cell migration and on colitis disease progression, the data
presented in the present study provide strong support for the de-
velopment of a combined ITK/RLK inhibitor as a potential ther-
apeutic strategy for Th1-mediated, and possibly Th17-mediated,
inflammatory diseases.
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FIGURE 6. PRN694 leads to impaired P-selectin binding and inhibits chemokine-induced CD4+ T cell migration. (A–E) Isolated naive CD4+ T cells
were cultured in the presence or absence of PRN694 (25 or 50 nM) for 72 h in each Th polarization condition. (A) Histograms show polarized CD4+ T cells
stained with recombinant P-selectin–human IgG fusion protein as an assay for P-selectin glycoprotein ligand 1 binding. Bold numbers above region indicate
the percentages of cells staining positively for P-selectin–Ig based on comparison with an isotype control stain; numbers at the left of each histogram
indicate the mean fluorescence intensity of P-selectin–Ig staining in each panel. (B) Graph shows a compilation of data from two independent experiments.
The data were normalized to the percentage of P-selectin–binding cells among each Th-polarizing condition in the absence of inhibitor. (C–E) Cultured
CD4+ T cells (5.0 3 105 cells) were plated in the upper chamber of HTS Transwell-96 well permeable supports (3.0-mm pore); bottom chambers were
loaded with diluted CXCL11 (100 ng/ml) (C), CCL20 (100 ng/ml) (D), or CCL25 (300 ng/ml) (E). After 3 h at 37˚C, the numbers of migrated cells were
counted by the flow cytometer. The chemotaxis index was calculated by dividing the number of cells that migrated in response to each chemokine by the
number of spontaneously migrated cells. *p , 0.05, **p , 0.01, ***p , 0.001.
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 1!
Supplemental Figure 1. PRN694 effect on CD4+ T cell proliferation in vitro and 2!
phosphorylation of PLCγ1 in vivo.  3!
(A-B) CFSE-labeled naïve CD4+ T cells were stimulated with anti-CD3/CD28 under 4!
different TH polarization conditions for 72hr. Histograms are shown to analyze the 5!
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Supplemental Figure 1
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C
! 2 
magnitude of CD4+ T cell proliferation. Mean fluorescence intensity of CFSE (Top, left) 6!
and percentages of more-divided (diluted) CD4+ T cells (Bottom, left) are shown (A). 7!
Calculated CD4+ T cell numbers of each cell division (Generation #1-5) by FlowJo 8!
software are shown. Data from three experiments were compiled (B). (C) Splenic CD4+ T 9!
cells isolated from vehicle-dosed (n=2) or PRN694-dosed (40 mg/kg) (2hr post-treatment, 10!
n=3; 6hr post-treatment, n=3) mice were stimulated with anti-CD3/CD28 for 5min and 11!
then lysed to examine the phosphorylation of PLCγ1 (Tyr783) by western blot. Both p-12!
PLCγ1 (Top) and total PLCγ1 (Bottom) are shown. 13!
! 3 
 14!
Supplemental Figure 2. Transcription factor and surface marker expression on 15!
transferred colitogenic CD4+ T cells from vehicle-treated and PRN694-treated mice. 16!
Supplemental Figure 2
A B
C
D
E
! 4 
(A-B) Isolated CD4+ T cells from each different organ of vehicle-treated or PRN694-17!
treated mice at 7 weeks of post-transfer were analyzed for T-bet expression, and the 18!
percentages of T-bet+ CD4+ T cells are shown. Graph shows a compilation of data from 3-19!
5 mice in each group. (C-E) Histograms show the expression of CTLA-4 (C), PD-1 (D), 20!
and GITR (E) on CD4+ Foxp3+ Treg cells isolated from spleen, mesenteric LN, intestinal 21!
epithelium (IEL), and lamina propria tissue of vehicle-treated (-) or PRN694-treated (+) 22!
mice. Graphs shown each panel represent the compiled data from 3-5 mice in each group.23!
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 24!
Supplemental Table 1. Inhibition of cytokines upon anti-CD3/CD28 stimulation of 25!
human PBMC by PRN694 using Human InflammationMap® v.1.0 biomarker 26!
panel.  27!
Shown are the levels of cytokine measured at each condition. The least detectable dose 28!
(LDD) was determined as the mean + 3 standard deviations of 20 blank readings. The 29!
LLOQ (Lower Limit of Quantitation) is the lowest concentration of an analyte in a 30!
sample that can be reliably detected. 31!
Samples Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 Sample 11 Sample 12
PRN694
anti-CD3/CD28
Alpha-1-Antitrypsin (AAT) mg/mL 3.8E-08 8.2E-08 0.000004 0.000002 0.0000019 0.0000046 0.0000038 0.0000028 0.0000049 0.0000034 0.0000029 0.0000044 0.0000024 0.0000021
Alpha-2-Macroglobulin (A2Macro) mg/mL 0.000098 0.000087 0.00045 0.00051 0.00052 0.00053 0.00052 0.00045 0.00053 0.00054 0.00053 0.00044 0.00053 0.00050
Beta-2-Microglobulin (B2M) ug/mL 0.000045 0.000051 0.0066 0.012 0.0082 0.014 0.029 0.021 0.014 0.016 0.020 0.0047 0.012 0.0067
Brain-Derived Neurotrophic Factor (BDNF) ng/mL 0.0046 0.0072 <0.0072 0.0096 <0.0072 <0.0072 <0.0072 <0.0072 <0.0072 <0.0072 <0.0072 <0.0072 <0.0072 <0.0072
C-Reactive Protein (CRP) ug/mL 0.0000034 7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06 <7.8E-06
Complement C3 (C3) mg/mL 1.6E-08 1E-07 0.0000025 0.0000016 0.000001 0.0000024 0.0000019 0.00000086 0.0000025 0.0000016 0.00000097 0.0000026 0.0000014 0.00000074
Eotaxin-1 pg/mL 1.9 29 <29 <29 <29 <29 <29 <29 <29 <29 <29 <29 <29 <29
Factor VII ng/mL 1.2 0.77 <0.77 <0.77 <0.77 <0.77 <0.77 <0.77 <0.77 <0.77 <0.77 <0.77 <0.77 <0.77
Ferritin (FRTN) ng/mL 0.013 0.021 0.24 0.42 0.20 0.44 0.78 0.45 0.49 0.72 0.51 0.29 0.48 0.35
Fibrinogen mg/mL 0.00000022 2.4E-07 0.000091 0.000047 0.000051 0.000082 0.000047 0.000058 0.000086 0.000047 0.000058 0.000087 0.000034 0.000052
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) pg/mL 3.2 18 <18 <18 <18 56 297 49 46 257 38 <18 <18 <18
Haptoglobin mg/mL 0.00000012 3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07 <3.2E-07
Intercellular Adhesion Molecule 1 (ICAM-1) ng/mL 0.35 0.26 <0.26 <0.26 <0.26 <0.26 0.28 <0.26 <0.26 0.28 <0.26 <0.26 <0.26 <0.26
Interferon gamma (IFN-gamma) pg/mL 0.49 0.30 <0.30 <0.30 <0.30 42 516 52 11 170 5.3 <0.30 <0.30 <0.30
Interleukin-1 alpha (IL-1 alpha) ng/mL 0.00030 0.00040 <0.00040 <0.00040 <0.00040 0.0023 0.0054 0.0032 0.00085 0.0042 0.00047 <0.00040 <0.00040 <0.00040
Interleukin-1 beta (IL-1 beta) pg/mL 0.30 0.57 2.8 .57 1.7 44 126 47 9.8 90 11 .57 .57 .57
Interleukin-1 receptor antagonist (IL-1ra) pg/mL 9.9 19 <19 <19 <19 184 218 211 406 417 652 <19 46 <19
Interleukin-2 (IL-2) pg/mL 1.0 1.7 1.7 1.7 1.7 594 1800 660 174 787 83 1.7 1.7 1.7
Interleukin-3 (IL-3) ng/mL 0.0011 0.0032 <0.0032 <0.0032 <0.0032 0.0036 0.0059 0.0038 <0.0032 <0.0032 <0.0032 <0.0032 <0.0032 <0.0032
Interleukin-4 (IL-4) pg/mL 4.4 5.9 5.9 5.9 5.9 75 131 86 33 97 16 5.9 5.9 5.9
Interleukin-5 (IL-5) pg/mL 1.0 2.6 2.6 2.6 2.6 5.6 19 7.2 3.1 13 2.6 2.6 2.6 2.6
Interleukin-6 (IL-6) pg/mL 0.84 2.2 22 2.2 13 104 192 117 18 58 88 2.2 2.2 3.7
Interleukin-7 (IL-7) pg/mL 2.1 1.8 <1.8 <1.8 <1.8 <1.8 <1.8 <1.8 <1.8 <1.8 2.5 <1.8 <1.8 <1.8
Interleukin-8 (IL-8) pg/mL 0.63 0.79 2630 489 1810 18500 15900 16700 14100 16100 19800 1100 1540 1650
Interleukin-10 (IL-10) pg/mL 1.1 1.4 <1.4 <1.4 <1.4 59 97 97 18 29 9.4 <1.4 <1.4 <1.4
Interleukin-12 Subunit p40 (IL-12p40) ng/mL 0.016 0.055 <0.055 <0.055 <0.055 <0.055 0.21 <0.055 <0.055 <0.055 <0.055 <0.055 <0.055 <0.055
Interleukin-12 Subunit p70 (IL-12p70) pg/mL 5.9 9.7 <9.7 <9.7 <9.7 <9.7 132 10 <9.7 24 <9.7 <9.7 <9.7 <9.7
Interleukin-15 (IL-15) ng/mL 0.12 0.079 <0.079 <0.079 <0.079 <0.079 <0.079 <0.079 <0.079 0.080 <0.079 <0.079 <0.079 <0.079
Interleukin-17 (IL-17) pg/mL 1.2 0.99 .99 .99 .99 12 8.6 10 5.0 3.7 1.6 .99 .99 .99
Interleukin-18 (IL-18) pg/mL 3.7 8.3 <8.3 <8.3 <8.3 <8.3 16 8.3 <8.3 12 <8.3 <8.3 <8.3 <8.3
Interleukin-23 (IL-23) ng/mL 0.12 0.080 <0.080 <0.080 <0.080 <0.080 <0.080 <0.080 <0.080 <0.080 <0.080 <0.080 <0.080 <0.080
Macrophage Inflammatory Protein-1 alpha (MIP-1 alpha) pg/mL 8.2 8.4 198 22 206 4790 5810 4040 6320 11800 5220 53 83 138
Macrophage Inflammatory Protein-1 beta (MIP-1 beta) pg/mL 4.0 6.2 1350 257 1460 22600 27900 23500 20300 39300 17400 297 391 651
Matrix Metalloproteinase-2 (MMP-2) ng/mL 1.3 0.87 1.4 <0.87 <0.87 6.1 7.9 7.7 5.0 9.9 7.1 <0.87 <0.87 <0.87
Matrix Metalloproteinase-3 (MMP-3) ng/mL 0.0066 0.012 <0.012 <0.012 <0.012 <0.012 <0.012 <0.012 <0.012 <0.012 <0.012 <0.012 <0.012 <0.012
Matrix Metalloproteinase-9 (MMP-9) ng/mL 5.0 7.9 <7.9 <7.9 <7.9 <7.9 <7.9 <7.9 <7.9 <7.9 <7.9 <7.9 <7.9 <7.9
Monocyte Chemotactic Protein 1 (MCP-1) pg/mL 4.6 9.0 508 206 298 1710 2760 2680 1550 3690 2150 51 144 50
Stem Cell Factor (SCF) pg/mL 18 23 <23 <23 <23 <23 <23 <23 <23 <23 <23 <23 <23 <23
T-Cell-Specific Protein RANTES (RANTES) ng/mL 0.00018 0.0010 0.26 0.13 0.18 0.48 0.30 0.41 0.51 0.28 0.40 0.32 0.066 0.24
Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) ng/mL 0.010 0.016 3.0 2.1 2.0 2.1 1.9 1.8 2.2 1.6 2.1 1.1 1.3 0.75
Tumor Necrosis Factor alpha (TNF-alpha) pg/mL 2.9 4.5 42 6.9 53 3830 7680 3270 2920 6880 2340 9.0 21 38
Tumor Necrosis Factor beta (TNF-beta) pg/mL 2.3 1.9 <1.9 <1.9 <1.9 11 34 13 5.3 24 3.5 <1.9 <1.9 <1.9
Tumor necrosis factor receptor 2 (TNFR2) ng/mL 0.0011 0.0057 0.077 0.071 0.053 0.21 0.24 0.22 0.23 0.26 0.26 0.053 0.097 0.052
Vascular Cell Adhesion Molecule-1 (VCAM-1) ng/mL 0.0090 0.057 <0.057 <0.057 <0.057 <0.057 <0.057 <0.057 <0.057 <0.057 <0.057 <0.057 <0.057 <0.057
Vascular Endothelial Growth Factor (VEGF) pg/mL 12 6.8 12 13 8.3 10 14 10 <6.8 10 <6.8 8.3 14 <6.8
Vitamin D-Binding Protein (VDBP) ug/mL 0.00002 0.000028 0.00037 0.000078 0.00014 0.00039 0.00013 0.00016 0.00039 0.000078 0.00018 0.00036 0.000066 0.00014
von Willebrand Factor (vWF) ug/mL 0.0016 0.0034 0.018 0.017 0.014 0.016 0.015 0.015 0.015 0.015 0.014 0.015 0.011 0.014
Analytes
- + + +
- - 20nM 5 MUnits
Myriad 
RBM 
LDD
Myriad 
RBM 
LLOQ
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Supplemental Table 2. Inhibition of cytokines upon anti-CD3 stimulation in 33!
vivo by PRN694 using RodentMap® v.3.0 biomarker panel.  34!
Shown are the levels of cytokine measured at each condition. The least detectable dose 35!
(LDD) was determined as the mean + 3 standard deviations of 20 blank readings. The 36!
Samples Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 Mouse 7 Mouse 8 Mouse 9 Mouse 10
Mouse 
11
Mouse 
12
PRN694
anti-CD3
Apolipoprotein A-I (Apo A-I) ug/mL 2.3 20 357 543 291 353 244 289 315 312 263 250 193 307
C-Reactive Protein Mouse (CRP Mouse) ug/mL 0.75 2.1 5.6 4.9 3.8 7.0 5.5 4.4 4.0 4.7 4.3 6.4 7.2 8.0
CD40 (CD40) pg/mL 6.7 13 44 47 38 48 56 81 61 69 62 48 72 116
CD40 Ligand (CD40-L) pg/mL 370 428 1040 787 443 1480 1310 1840 1130 1480 1310 3740 3150 2960
Eotaxin pg/mL 3.5 6.2 953 1100 1200 2770 3050 3910 2160 3160 2270 6940 8140 6050
Epidermal Growth Factor Mouse (EGF Mouse) pg/mL 18 15 20 17 20 35 40 44 31 29 35 51 60 49
Factor VII ng/mL 25 19 25 38 27 54 52 68 38 51 47 82 96 70
Fibrinogen ug/mL 231 510 73100 89600 70100 66000 76900 62300 73900 92600 74100 75900 80600 117000
Fibroblast Growth Factor 9 (FGF-9) ng/mL 2.4 2.9 6.6 4.2 5.2 16 16 18 9.3 14 14 12 14 16
Fibroblast Growth Factor basic (FGF-basic) ng/mL 12 15 <15 <15 <15 <15 <15 <15 <15 <15 <15 <15 <15 <15
Granulocyte Chemotactic Protein-2 Mouse (GCP-2 Mouse) ng/mL 0.16 0.49 1.4 1.4 1.3 3.6 3.4 3.2 2.2 2.4 1.8 4.1 4.8 4.1
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) pg/mL 4.1 6.8 <6.8 <6.8 <6.8 77 281 114 18 33 37 19 32 19
Growth Hormone (GH) ng/mL 1.9 1.6 5.7 3.0 3.0 3.0 3.5 3.5 3.5 3.3 3.0 6.0 4.2 2.6
Growth-Regulated Alpha Protein (KC/GRO) ng/mL 0.012 0.026 0.48 0.74 1.3 14 11 14 5.0 7.4 7.0 6.4 8.0 6.2
Haptoglobin ug/mL 118 121 131 160 126 125 125 125 127 125 127 144 146 150
Immunoglobulin A (IgA) ug/mL 18 19 258 1460 117 419 342 169 368 144 431 218 258 346
Insulin uIU/mL 4.1 6.3 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3 <6.3
Interferon gamma (IFN-gamma) pg/mL 15 38 <38 <38 <38 128 152 98 <38 40 47 54 86 80
Interferon gamma Induced Protein 10 (IP-10) pg/mL 6.6 7.1 292 1740 165 2940 3910 2780 737 2010 1490 3450 3470 4190
Interleukin-1 alpha (IL-1 alpha) pg/mL 108 132 156 <132 <132 327 312 265 219 281 281 327 296 357
Interleukin-1 beta (IL-1 beta) ng/mL 6.5 3.5 <3.5 <3.5 <3.5 <3.5 <3.5 <3.5 <3.5 <3.5 <3.5 <3.5 <3.5 <3.5
Interleukin-2 (IL-2) pg/mL 25 49 <49 <49 <49 428 761 541 <49 <49 <49 69 146 <49
Interleukin-3 (IL-3) pg/mL 2.9 4.3 <4.3 <4.3 <4.3 9.4 14 8.4 <4.3 4.5 5.4 <4.3 6.4 5.4
Interleukin-4 (IL-4) pg/mL 52 68 <68 <68 <68 106 633 224 <68 73 87 <68 100 <68
Interleukin-5 (IL-5) ng/mL 0.47 0.75 .75 .75 .75 0.92 0.76 0.82 1.3 <0.75 <0.75 3.6 3.7 0.87
Interleukin-6 (IL-6) pg/mL 2.6 3.8 45 21 17 700 1260 461 206 307 152 119 510 269
Interleukin-7 (IL-7) ng/mL 0.086 0.12 0.14 <0.12 0.14 0.54 0.48 0.69 0.24 0.36 0.39 0.55 0.48 0.53
Interleukin-10 (IL-10) pg/mL 91 220 220 220 220 762 1090 979 271 440 504 440 590 376
Interleukin-11 (IL-11) pg/mL 40 70 70 70 70 122 122 110 76 110 110 103 122 155
Interleukin-12 Subunit p70 (IL-12p70) ng/mL 0.12 0.14 .14 .14 .14 0.40 0.45 0.25 0.14 0.17 0.25 0.22 0.33 0.31
Interleukin-17A (IL-17A) ng/mL 0.0071 0.0073 <0.0073 <0.0073 <0.0073 0.16 0.16 0.13 0.029 0.037 0.042 0.042 0.056 0.045
Interleukin-18 (IL-18) ng/mL 6.2 8.0 14 14 12 14 12 14 16 14 14 16 18 20
Leptin ng/mL 0.026 0.053 1.1 0.87 0.44 0.25 0.58 0.90 1.3 1.0 1.3 0.92 0.64 1.7
Leukemia Inhibitory Factor (LIF) pg/mL 218 463 487 <463 <463 1530 1250 1530 583 1010 869 1810 2360 1710
Lymphotactin pg/mL 19 21 93 75 67 1120 1340 1420 346 517 508 713 989 919
Macrophage Colony-Stimulating Factor-1 (M-CSF-1) ng/mL 0.033 0.051 5.7 7.4 5.5 6.1 5.4 5.1 5.9 5.1 5.8 6.7 7.3 7.0
Macrophage-Derived Chemokine  (MDC) pg/mL 34 55 1280 1220 910 2180 3000 2900 1500 1960 1500 3870 4270 3640
Macrophage Inflammatory Protein-1alpha (MIP-1 alpha) ng/mL 4.1 3.3 3.3 3.3 3.3 4.2 3.3 4.2 3.7 3.3 3.3 5.6 6.1 6.1
Macrophage Inflammatory Protein-1 beta (MIP-1 beta) pg/mL 47 53 1590 960 714 20100 22800 25200 5960 9790 10600 10200 17100 12700
Macrophage Inflammatory Protein-1 gamma (MIP-1 gamma) ng/mL 0.45 0.67 10 11 12 14 14 11 13 13 12 19 17 18
Macrophage Inflammatory Protein-2 (MIP-2) pg/mL 5.3 11 52 32 36 5210 3360 3420 819 2270 1040 711 1380 1520
Macrophage Inflammatory Protein-3 beta (MIP-3 beta) ng/mL 0.36 1.2 2.1 2.5 1.5 3.1 4.0 4.5 2.5 3.4 2.4 6.2 7.0 5.4
Matrix Metalloproteinase-9 (MMP-9) ng/mL 9.9 14 66 66 48 168 162 125 109 100 104 100 111 106
Monocyte Chemotactic Protein 1 (MCP-1) pg/mL 4.9 7.9 1810 1460 1550 4390 3630 4680 3170 3490 3780 4110 4250 4650
Monocyte Chemotactic Protein 3 (MCP-3) pg/mL 4.2 4.4 1800 1470 2060 3820 4150 4170 3110 3100 3610 4210 4250 4430
Monocyte Chemotactic Protein-5 (MCP-5) pg/mL 1.7 2.3 172 68 265 1070 1180 676 381 374 739 985 1320 1080
Myeloperoxidase (MPO) ng/mL 0.48 0.66 102 102 61 115 140 146 100 112 104 191 182 174
Myoglobin ng/mL 5.7 6.0 81 15 9.6 380 64 32 109 45 13 103 58 156
Oncostatin-M (OSM) ng/mL 0.097 0.21 0.42 0.22 0.27 1.0 0.96 1.1 0.62 1.0 0.88 0.98 1.2 1.2
Plasminogen Activator Inhibitor 1 (PAI-1) ng/mL 0.015 0.034 1.5 9.2 0.73 9.0 13 7.6 3.4 10 9.3 11 12 11
Resistin ng/mL 0.013 0.039 <0.039 <0.039 <0.039 <0.039 <0.039 <0.039 <0.039 <0.039 <0.039 <0.039 <0.039 <0.039
Serum Amyloid P-Component (SAP) ug/mL 6.4 9.0 45 45 42 56 49 42 39 47 48 42 53 62
Stem Cell Factor (SCF) pg/mL 153 290 1230 934 1110 3010 2470 2740 2010 2270 2410 2780 3130 2940
T-Cell-Specific Protein RANTES (RANTES) pg/mL 0.026 0.028 0.031 <0.028 <0.028 0.27 0.20 0.29 0.059 0.049 0.092 0.10 0.18 0.12
Thrombopoietin ng/mL 30 60 <60 <60 76 68 <60 60 68 68 60 84 99 95
Tissue Inhibitor of Metalloproteinases 1 Mouse (TIMP-1 Mouse) ng/mL 0.021 0.084 1.5 1.6 1.3 1.8 2.0 1.2 1.2 1.3 1.1 4.6 4.5 2.7
Tumor Necrosis Factor alpha (TNF-alpha) ng/mL 0.029 0.11 <0.11 <0.11 <0.11 0.28 0.23 0.25 0.17 0.16 0.22 0.20 0.23 0.23
Vascular Cell Adhesion Molecule-1 (VCAM-1) ng/mL 3.3 5.4 732 894 682 970 953 814 1040 1090 877 933 1060 1360
Vascular Endothelial Growth Factor A (VEGF-A) pg/mL 222 158 717 474 756 2080 1960 2280 1230 1750 1690 2000 2360 2320
von Willebrand factor (vWF) ng/mL 27 45 345 351 457 385 589 446 671 578 731 639 677 655
+
6hr
+-
-
-
+ 1hr
Analytes Units
Myriad 
RBM 
LDD
Myriad 
RBM 
LLOQ
Supplemental Table 2
! 7 
LLOQ (Lower Limit of Quantitation) is the lowest concentration of an analyte in a 37!
sample that can be reliably detected. 38!
